Immunotherapy in hepatocellular cancer patients with mild to severe liver dysfunction: adjunctive role of the ALBI grade
Abstract: Immune checkpoint inhibitors (ICI) have shown positive results in patients with hepatocellular carcinoma (HCC). As liver function contributes to prognosis, its precise assessment is necessary for the safe prescribing and clinical development of ICI in HCC. We tested the accuracy of the albumin-bilirubin (ALBI) grade as an alternative prognostic biomarker to the Child-Turcotte-Pugh (CTP). In a prospectively maintained multi-centre dataset of HCC patients, we assessed safety and efficacy of ICI across varying levels of liver dysfunction described by CTP (A to C) and ALBI grade and evaluated uni- and multi-variable predictors of overall (OS) and post-immunotherapy survival (PIOS). We studied 341 patients treated with programmed-death pathway inhibitors (n = 290, 85%). Pre-treatment ALBI independently predicted for OS, with median OS of 22.5, 9.6, and 4.6 months across grades (p < 0.001). ALBI was superior to CTP in predicting 90-days mortality with area under the curve values of 0.65 (95% CI 0.57–0.74) versus 0.63 (95% CI 0.54–0.72). ALBI grade at ICI cessation independently predicted for PIOS (p < 0.001). Following adjustment for ICI regimen, neither ALBI nor CTP predicted for overall response rates or treatment-emerging adverse events (p > 0.05). ALBI grade identifies a subset of patients with prolonged survival prior to and after ICI therapy, lending itself as an optimal stratifying biomarker to optimise sequencing of systemic therapies in advanced HCC
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
Cancers. - 12, 7 (2020) , 1862, ISSN: 2072-6694
- Schlagwort
-
Bilirubin
Biomarker
Überleben
Immuntherapie
- Ereignis
-
Veröffentlichung
- (wo)
-
Freiburg
- (wer)
-
Universität
- (wann)
-
2020
- Urheber
-
Pinato, David James
Kaneko, Takahiro
Bettinger, Dominik
Personeni, Nicola
Rimassa, Lorenza
Huang, Yi-Hsiang
- DOI
-
10.3390/cancers12071862
- URN
-
urn:nbn:de:bsz:25-freidok-1666957
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:51 MESZ
Datenpartner
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Pinato, David James
- Kaneko, Takahiro
- Bettinger, Dominik
- Personeni, Nicola
- Rimassa, Lorenza
- Huang, Yi-Hsiang
- Universität
Entstanden
- 2020
Ähnliche Objekte (12)
HCC-Biomarker in der Diagnostik und Therapie des Hepatozellulären Karzinoms (HCC) in verschiedenen Phasen der Erkrankung
Early antibiotic exposure is not detrimental to therapeutic effect from immunotherapy in hepatocellular carcinoma
Prediction of survival among patients receiving transarterial chemoembolization for hepatocellular carcinoma : : a response‐based approach
Klinisches Vorgehen bei Leberabszessen
Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study
Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study
Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC
Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as prognostic biomarkers in unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab
Impact of corticosteroid therapy on the outcomes of hepatocellular carcinoma treated with immune checkpoint inhibitor therapy
A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma
The systemic inflammatory response identifies patients with adverse clinical outcome from immunotherapy in hepatocellular carcinoma
Evaluation einer Definition und der Prävalenz des hyperdynamischen Kreislaufes bei Patienten mit Leberzirrhose und Aszites
HCC-Biomarker in der Diagnostik und Therapie des Hepatozellulären Karzinoms (HCC) in verschiedenen Phasen der Erkrankung
Early antibiotic exposure is not detrimental to therapeutic effect from immunotherapy in hepatocellular carcinoma
Prediction of survival among patients receiving transarterial chemoembolization for hepatocellular carcinoma : : a response‐based approach
Klinisches Vorgehen bei Leberabszessen
Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study
Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study
Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC
Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as prognostic biomarkers in unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab
Impact of corticosteroid therapy on the outcomes of hepatocellular carcinoma treated with immune checkpoint inhibitor therapy
A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma
The systemic inflammatory response identifies patients with adverse clinical outcome from immunotherapy in hepatocellular carcinoma
Evaluation einer Definition und der Prävalenz des hyperdynamischen Kreislaufes bei Patienten mit Leberzirrhose und Aszites
HCC-Biomarker in der Diagnostik und Therapie des Hepatozellulären Karzinoms (HCC) in verschiedenen Phasen der Erkrankung
Early antibiotic exposure is not detrimental to therapeutic effect from immunotherapy in hepatocellular carcinoma
Prediction of survival among patients receiving transarterial chemoembolization for hepatocellular carcinoma : : a response‐based approach
Klinisches Vorgehen bei Leberabszessen
Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study
Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study
Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC
Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as prognostic biomarkers in unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab
Impact of corticosteroid therapy on the outcomes of hepatocellular carcinoma treated with immune checkpoint inhibitor therapy
A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma
The systemic inflammatory response identifies patients with adverse clinical outcome from immunotherapy in hepatocellular carcinoma